Category: Mergers and Acquisitions

January 11, 2022

Pfizer and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, have entered into a development and option agreement under which Pfizer will have the option to license, on a non-exclusive […]

December 1, 2021

Merger and acquisition activity has been rather slow in the biopharma industry so far this year. But, by one team of analysts’ calculations, large drugmakers will have big piles of cash to deploy in 2022. Eighteen large-cap U.S. and European […]

November 3, 2021

Novartis will partner with Dunad Therapeutics to develop oral covalent and protein degrading small molecule drugs for undisclosed diseases, through a collaboration that could generate more than $1.3 billion for the year-old developer of next-generation targeted protein degradation therapies—and revive […]

October 14, 2021

Aceto continued its aggressive expansion plans with the acquisition of A&C Bio Buffer, marking the company’s sixth acquisition in under a year. A&C Bio, which is based in Limerick, Ireland, produces biological buffers, process solutions, cleaning solutions and chemical blends […]

September 30, 2021

Merck & Co. has agreed to acquire Acceleron Pharma for $11.5 billion, the companies said today, in a deal designed to bolster the buyer’s cardiovascular and blood drug portfolios with a Phase III pulmonary arterial hypertension (PAH)drug and a marketed […]

September 29, 2021

AstraZeneca is continuing to build out its rare disease pipeline, pulling the trigger on an option to buy Caelum Biosciences that it picked up in its takeover of Alexion. The buyout gives AstraZeneca control of a phase 3 treatment for […]

September 22, 2021

Novartis have announced that it has acquired Arctos Medical, adding a pre-clinical optogenetics-based Adeno-associated viruses (AAV) gene therapy programme and Arctos’ proprietary technology to its ophthalmology portfolio. The acquisition aims to more efficiently develop treatments for patients with vision loss […]

September 10, 2021

Boehringer Ingelheim will use the same concept in a new research collaboration with San Francisco-based Twist Bioscience, harnessing its antibody libraries to discover therapeutic antibodies that work against a range of BI targets. Twist’s ability to manufacture DNA at scale […]

September 8, 2021

The deal with see Adaptimmune receive $150m upfront, another $150m over the next five years and then milestone payments potentially exceeding $3bn in aggregate sales, as well as royalties. Unlike other leaders in next-generation cell therapies, the partners will use […]

August 23, 2021

Biotechs targeting the “don’t eat me” signal cancer cells use to avoid the immune system are getting gobbled up. Pfizer is the latest company to buy its way into the space, splashing out $2.3 billion to acquire Trillium Therapeutics for […]

August 13, 2021

On Aug 12, 2021, Lykan Bioscience, a US-based contract development and manufacturing organization (CDMO) focused on cell-based therapies, and Vineti, a US-based enterprise software platform company, announced a partnership that will combine Lykan’s purpose-built, multi-product cell therapy manufacturing facility located […]

July 28, 2021

Just two months after getting a swift approval for its closely watched KRAS lung cancer drug Lumakras, Amgen is not resting on its laurels and has penned a major new buyout deal to further boost its oncology pipeline. The biopharma […]